Results 31 to 40 of about 2,668 (112)

Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem‐Resistant Klebsiella pneumoniae (CRKP) Infections

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang   +5 more
wiley   +1 more source

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

open access: yesPharmaceuticals, 2022
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and ...
Luigi Principe   +11 more
doaj   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

open access: yesMedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy   +9 more
wiley   +1 more source

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

open access: yesClinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen   +3 more
wiley   +1 more source

A review of antibiotic safety in pregnancy—2025 update

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen   +8 more
wiley   +1 more source

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

open access: yesInfection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA   +4 more
doaj  

Epidemiology, Treatment, and Outcomes of Gram‐Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients

open access: yesClinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg   +11 more
wiley   +1 more source

In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates

open access: yesJournal of Global Antimicrobial Resistance, 2023
: Objectives: A novel ß-lactam-β-lactamase inhibitor (BLBI), meropenem (MEM), combined with the boronate-based inhibitor vaborbactam (VAB), has recently been introduced for the treatment of infections caused by Klebsiella pneumoniae carbapenemase (KPC ...
Jacqueline Findlay   +2 more
doaj   +1 more source

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

open access: yesEFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards)   +28 more
wiley   +1 more source

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside

open access: yesAntibiotics, 2021
Gram-negative bacilli septic thrombosis (GNB-ST) represents a subtle and often misleading condition, potentially fatal if not recognized early and requiring prolonged antimicrobial therapy and anticoagulation.
Alessandra Oliva   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy